Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline

Satoshi Matsuoka1,2, Hidehiro Kaneko1,3, Tatsuya Kamon1, Yuta Suzuki1,4, Yuichiro Yano5,6, Akira Okada7, Hidetaka Itoh1, Kojiro Morita8, Akira Fukui9, Katsuhito Fujii1,2, Nobuaki Michihata10, Taisuke Jo10, Norifumi Takeda1, Hiroyuki Morita1, Sunao Nakamura2, Takashi Yokoo9, Akira Nishiyama11, Koichi Node12, Hideo Yasunaga13 and Issei Komuro1

1 The Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
2 The Department of Cardiology, New Tokyo Hospital, Matsudo, Japan.
3 The Department of Advanced Cardiology, The University of Tokyo, Tokyo, Japan.
4 Department of Rehabilitation Science, Graduate School of Medical Sciences, Kitasato University, Kanagawa, Japan.
5 YCU Center for Novel and Exploratory Clinical Trials, Yokohama City University Hospital, Yokohama, Japan.
6 The Department of Family Medicine and Community Health, Duke University, Durham, NC, USA
7 The Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
8 Global Nursing Research Center, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan.
9 Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
10 The Department of Health Services Research, The University of Tokyo, Tokyo, Japan.
11 Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
12 Department of Cardiovascular Medicine, Saga University, Saga, Japan.
13 The Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.

Aim: We investigated whether retinal arteriolosclerosis (RA) could be used for cardiovascular disease (CVD) risk stratification of individuals categorized according to the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Blood Pressure (BP) guideline.

Methods: We studied 291,522 participants without a history of CVD and not taking any BP-lowering medications from the JMDC Claims Database. RA was defined as Keith–Wagener–Barker system grade ≥ 1. Each participant was classified into one of the six groups: (1) normal or elevated BP without RA, (2) normal or elevated BP with RA, (3) stage 1 hypertension without RA, (4) stage 1 hypertension with RA, (5) stage 2 hypertension without RA, and (6) stage 2 hypertension with RA.

Results: Median (interquartile range) age was 46 (40–53) years, and 141,397 (48.5%) of the participants were men. During a mean follow-up of 1,223 ± 830 days, 527 myocardial infarction (MI), 5,718 angina pectoris, 2,890 stroke, and 5,375 heart failure (HF) events occurred. Multivariable Cox regression analyses revealed that the risk of CVD increased with BP category, and this association was pronounced by the presence of RA. Compared with normal or elevated BP without RA, the hazard ratios (HRs) for MI (HR 1.17, 95% CI 0.93–1.47) were higher in stage 1 hypertension without RA. The HRs for MI further increased in stage 1 hypertension with RA (1.86 [1.17–2.95]). This association was present in stroke and HF.

Conclusion: Incorporation of the assessment for RA may facilitate the CVD risk stratification of people classified based on the 2017 ACC/AHA BP guideline, particularly for those categorized in stage 1 hypertension.

Key words: Retinal arteriolosclerosis, Hypertension, Cardiovascular disease, Risk

Non-standard Abbreviations and Acronyms: ACC = American College of Cardiology, AHA = American Heart Association, AP = Angina Pectoris, BP = Blood Pressure, CI = Confidence Interval, CVD = Cardiovascular Disease, HF = Heart Failure, HR = Hazard Ratio, MI = Myocardial Infarction, RA = Retinal arteriolosclerosis

See editorial vol. 29: 1430-1431


**Methods**

The JMDC Claims Database is available for anyone who purchases it from JMDC Inc. (https://www.jmdc.co.jp/en/index).

**Study Population**

This study is an observational analysis using the JMDC Claims Database (JMDC Inc., Tokyo, Japan), a nationwide health claims database, conducted between January 2005 and April 2020. The JMDC Claims Database includes the employed population and their family members (e.g., their spouse or children). Detailed information on this database is described elsewhere. The JMDC Claims Database includes health insurance claims records of more than 60 insurers. It also contains the workplace employees' annual health check-up data, including demographics, medical history, medications, and hospital claims recorded using the International Classification of Diseases, 10th Revision (ICD-10) coding. We extracted the records of 373,700 individuals with available retinography and BP data at health check-up. We excluded the records of individuals aged <20 years, taking BP-lowering medications, with missing data on BP-lowering medications, with history of CVD or hemodialysis, and with missing data on body mass index, waist circumference, lipid profile and fasting plasma glucose, medications for dyslipidemia or diabetes, and cigarette smoking, leaving a final analytic sample of 291,522 participants.

**Ethics**

We conducted this study according to the ethical guidelines of our institution (approval by the Ethics Committee of the University of Tokyo: 2018-10862) and in accordance with the principles of the Declaration of Helsinki. The requirement for informed consent was waived because all data from the JMDC Claims Database were de-identified.

**BP Classification According to the 2017 ACC/AHA Guidelines**

In the Japanese health check-up system, BP was measured according to the recommended protocol of the Japanese Ministry of Health, Labour and Welfare.

---

**Introduction**

High blood pressure (BP) and hypertension are associated with a greater risk of cardiovascular disease (CVD). Current epidemiological data show that most of CVD events occur in individuals with BP < 140/90 mmHg. The Systolic Blood Pressure Intervention Trial demonstrated that intensive BP control that targeted systolic BP (SBP) <120 mmHg significantly reduced the risk of subsequent CVD events compared with standard BP control that targeted SBP <140 mmHg. Taking these data into consideration, the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) BP guidelines lowered the BP threshold for hypertension from SBP and diastolic BP (DBP) of 140/90 mmHg to SBP/DBP of 130/80 mmHg. The 2017 ACC/AHA BP guideline newly defines stage 1 hypertension as 130–139/80–89 mmHg and suggests a 10-year predicted atherosclerotic CVD risk to assess the individual's CVD risk and to determine the management strategy. However, this risk assessment is known to overestimate the CVD risk. Further, the risk of heart failure (HF), which is currently increasing its clinical importance, cannot be assessed by these equations. Atherosclerosis is a key factor of the pathology for various CVDs, and therefore, detecting changes associated with atherosclerosis, such as increase in carotid intima media thickness or coronary artery calcium, is known to help identify population at a high risk of future CVD, including HF. Retinal arteriolosclerosis (RA), assessed using the Keith–Wagener–Barker system, is also an established marker of atherosclerosis and is reported to be associated with incident CVD events. Furthermore, the assessment of RA is widely used for the screening of atherosclerosis in the general population because of its simplicity and low invasiveness. Therefore, RA could be used as a marker of atherosclerosis, which could stratify the CVD risk of the general population classified using the 2017 ACC/AHA BP guideline. In this study, we aimed to clarify whether RA could help identify people at a high risk of future CVD among the general population classified based on the 2017 ACC/AHA BP guideline using a nationwide epidemiological database.
Retinal Arteriolar sclerosis, BP, CVD Risk

Fig. 1. Flowchart
We extracted the records of 373,700 individuals with available retinography and BP data. We excluded the records of individuals aged <20 years (n=519), taking BP-lowering medications (n=40,209), with missing data on BP-lowering medications (n=5,625), with history of CVD or hemodialysis (n=9,692), and with missing data on body mass index (n=157), waist circumference (n=8,076), lipid profile and fasting plasma glucose (n=17,833), medications for dyslipidemia or diabetes (n=16), and cigarette smoking (n=51), leaving a final analytic sample of 291,522 participants.

by healthcare professionals using a standard sphygmomanometer or an automated device on the right arm after participants had rested for 5 min in a seated position. The measurements were performed twice at an interval of ≥ 1 min, and the average of two measurements on a single occasion was used for analyses. The participants were categorized as having normal BP, elevated BP, stage 1 hypertension, or stage 2 hypertension. The normal BP group included participants with untreated SBP <120 mm Hg and untreated DBP <80 mm Hg. The elevated BP group included participants with untreated SBP of 120–129 mm Hg and untreated DBP <80 mm Hg. The stage 1 hypertension group included participants with untreated SBP of 130–139 mmHg or untreated DBP of 80–89 mmHg. The stage 2 hypertension group included participants with untreated SBP ≥ 140 mm Hg or untreated DBP ≥ 90 mm Hg6).

Retinal Arteriolar sclerosis
Nonmydriatic retinal photography of the right or left eye was conducted by experienced medical laboratory technicians. Retinal microvascular abnormalities were evaluated using the Keith–Wagener–Barker system, as previously described24, 25): normal; Keith–Wagener–Barker system grade 1, defined as mild or moderate generalized narrowing or sclerosis of the retinal arteries; Keith–Wagener–Barker system grade 2, defined as moderate to marked sclerosis of the retinal arteries, moderate focal narrowing of the retinal arteries, or arteriosclerotic retinopathy or thrombosis of the retinal veins; Keith–Wagener–Barker system grade 3, defined as angiospastic retinopathy that is characterized by edema, cotton-wool spots, and hemorrhages in the retina, in addition to marked sclerosis of the retinal arteries; and Keith–Wagener–Barker system grade 4, defined as measurable edema of the disks in addition to grade 3 findings. RA was defined as Keith–Wagener–Barker system grade ≥ 1.

Stratification Based on BP Classification and RA
Participants were classified into six groups: (1) normal BP or elevated BP without RA, (2) normal BP or elevated BP with RA, (3) stage 1 hypertension without RA, (4) stage 1 hypertension with RA, (5) stage 2 hypertension without RA, and (6) stage 2 hypertension with RA.

Other Measurements
Data, including body mass index, waist circumference, history of diabetes mellitus, dyslipidemia, and CVD, and fasting laboratory values were collected using standardized protocols across study centers. Information on cigarette smoking (current or non-current) was self-reported. Obesity was defined as body mass index (BMI) ≥ 25 kg/m²26). High waist circumference was defined as waist
circumference ≥ 85 cm for men and ≥ 90 cm for women. Diabetes mellitus was defined as fasting blood glucose ≥ 126 mg/dL or use of glucose-lowering medications. Dyslipidemia was defined as low-density lipoprotein cholesterol ≥ 140 mg/dL, high-density lipoprotein cholesterol <40 mg/dL, triglycerides ≥ 150 mg/dL, or use of lipid-lowering medications.

Outcomes

Outcomes were collected between January 2005 and April 2020. The primary outcomes included myocardial infarction (MI) (ICD-10: I210, I211, I212, I213, I214, I219), AP (ICD-10: I200, I201, I208, I209), stroke (ICD-10: I630, I631, I632, I633, I634, I635, I636, I638, I639, I600, I601, I602, I603, I604, I605, I606, I607, I608, I609, I610, I611, I613, I614, I615, I616, I619, I629, G459), and HF (ICD-10: I500, I501, I509, I110). Each CVD event was analyzed separately. For example, if a participant had a stroke and then had an MI a month later, both the stroke and MI events were counted as separate outcomes. For an individual who left his/her insurance, we defined the last follow-up date as the date of leaving the insurance.

Statistical Analysis

Data are presented as median (interquartile range) for continuous variables or number (percentage) for categorical variables. P values were calculated using the analysis of variance for continuous variables and chi-squared tests for categorical variables. We conducted Cox regression analyses to assess the association of six groups stratified by BP classification and RA with subsequent risk for CVD outcomes. Hazard ratios (HRs) were calculated in an unadjusted model and after adjustment for potential confounders, including age, sex, obesity, high waist circumference, diabetes mellitus, dyslipidemia, and cigarette smoking. We conducted multiple imputation for missing data, as previously described. On the assumption of data missing at random, we imputed missing data using the chained equation method with 20 iterations, as described by Aloisio. HRs and standard errors were obtained using Rubin’s rules. We conducted subgroup analyses stratified by age or sex. A P-value of <0.05 was considered statistically significant. Statistical analyses were performed using the SPSS software version 25 (IBM corp., Armonk, NY, USA) and STATA version 16 (StataCorp LLC, College Station, TX, USA).

Results

Clinical characteristics of the study participants are presented in Table 1. Overall, the median (interquartile range) age was 46 (40–53) years, and 141,397 (48.5%) of the participants were men. The participants were getting older with increasing BP classification, and those with RA. The prevalence of obesity, high waist circumference, diabetes mellitus, and dyslipidemia was higher in participants with advanced BP classification and RA.

The mean follow-up period of the overall study population was 1,223 ± 830 days. The mean ± SD follow-up period of each group was as follows: 1,223 ± 828 days for normal/elevated BP without RA, 1,252 ± 788 days for normal/elevated BP with RA, 1,231 ± 833 for stage 1 hypertension without RA, 1,237 ± 824 days for stage 1 hypertension with RA, 1,196 ± 852 days for stage 2 hypertension without RA, and 1,200 ± 824 days for stage 2 hypertension with RA. During the follow-up period, 527 MI, 5,718 AP, 2,890 stroke, and 5,375 HF events were recorded. Although there was no statistically significant difference in the incidence of MI between participants having normal or elevated BP without RA and those having stage 1 hypertension without RA, the incidence of MI was higher in participants having stage 1 hypertension with RA (HR 1.86, 95% confidence interval [CI] 1.17–2.95) compared with those having normal or elevated BP without RA. The risk of MI further increased in participants having stage 2 hypertension without RA (HR 2.04, 95% CI 1.61–2.59) and with RA (HR 2.54, 95% CI 1.77–3.65) (Fig. 2A). The risk of AP was higher in both participants having stage 1 hypertension without and with RA compared with those having normal or elevated BP without RA. It was also higher in participants having stage 2 hypertension without RA (HR 1.44, 95% CI 1.33–1.56) and further increased in those having stage 2 hypertension with RA (HR 1.78, 95% CI 1.56–2.03) (Fig. 2B). The risk of stroke was higher in participants having normal or elevated BP with RA (HR 1.34, 95% CI 1.12–1.61) than those having normal or elevated BP without RA. It was also higher in participants having stage 1 hypertension (HR 1.20, 95% CI 1.09–1.33) or stage 2 hypertension (HR 1.83, 95% CI 1.65–2.04) without RA. This association was pronounced in participants having stage 1 hypertension (HR 1.74, 95% CI 1.41–2.13) or stage 2 hypertension (HR 2.48, 95% CI 2.11–2.91) with RA (Fig. 2C). The risk of HF was higher in participants having stage 1 hypertension (HR 1.28, 95% CI 1.19–1.37) or stage 2 hypertension (HR 1.91, 95% CI 1.76–2.06) without RA compared with those having normal or elevated BP without RA. This association was further stronger in participants having stage 1 hypertension...
Clinical Characteristics

were aged ≥ 50 years with RA who had a prior history of CVD and not taking any BP-lowering medications, revealed that the association between BP category based on the 2017 ACC/AHA BP guideline and future CVD events could be pronounced by the presence of RA assessed using the Keith–Wagener-Barker system grade ≥ 1. ACC; American College of Cardiology, AHA; American Heart Association, LDL-C; low-density lipoprotein cholesterol, HDL-C; high-density lipoprotein cholesterol.

Further, in participants having normal or elevated BP, RA was associated with a higher incidence of stroke in those aged ≥ 50 years (Table 2A), in those aged < 50 years (Table 2B), and stroke and HF in men (Table 2C).

Discussion

The current analyses using a nationwide epidemiological database, including a general population of approximately 300,000 adults without prior history of CVD and not taking any BP-lowering medications, revealed that the association between BP category based on the 2017 ACC/AHA BP guideline and future CVD events could be pronounced by the presence of RA assessed using the Keith–Wagener–Barker system.

According to the 2017 ACC/AHA BP guideline, approximately 30 million individuals are newly diagnosed with hypertension in the United States.2D. Further, in participants having normal or elevated BP, RA was associated with a higher incidence of stroke in those aged ≥ 50 years (Table 2A), in those aged < 50 years (Table 2B), and stroke and HF in men (Table 2C).

Table 1. Clinical Characteristics

| Blood Pressure Category according to the 2017 ACC/AHA Guideline | Retinal arteriolosclerosis | Retinal arteriolosclerosis | Retinal arteriolosclerosis | P-value |
|---------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|---------|
| Normal Blood Pressure/Elevated Blood Pressure                | (-)                         | (+)                         | (-)                         | (+)     |        |
| Number                                                        | 195,678                      | 7,830                       | 51,884                      | 4,473   | 25,693 | 5,964 | ----- |
| Age, years                                                    | 44 (40-51)                   | 53 (47-60)                  | 48 (42-55)                  | 55 (48-61) | 50 (44-57) | 53 (48-60) | <0.001 |
| Male sex, n (%)                                               | 82,875 (42.4)                | 3,950 (50.4)                | 32,144 (62.0)               | 2,961 (66.2) | 15,661 (61.0) | 3,806 (63.8) | <0.001 |
| Body Mass Index, kg/m²                                         | 21.4 (19.6-23.6)             | 22.1 (20.1-24.2)            | 23.3 (21.2-25.8)            | 23.5 (21.5-25.8) | 24.2 (21.8-27.1) | 24.4 (22.0-27.0) | <0.001 |
| Obesity, n (%)                                                | 28,855 (14.7)                | 1,441 (18.4)                | 16,819 (32.4)               | 1,478 (33.0) | 10,870 (42.3) | 2,579 (43.2) | <0.001 |
| Waist Circumference, cm                                       | 78 (72-84)                   | 80 (74-86)                  | 83 (77-90)                  | 84 (79-90) | 85 (79-93) | 86 (80-93) | <0.001 |
| High Waist Circumference, n (%)                               | 33,581 (17.2)                | 1,869 (23.9)                | 19,208 (37.0)               | 1,800 (40.2) | 11,825 (46.0) | 2,892 (48.5) | <0.001 |
| Systolic Blood Pressure, mmHg                                 | 109 (101-117)                | 112 (104-120)               | 128 (122-133)               | 130 (124-134) | 144 (138-151) | 148 (141-158) | <0.001 |
| Diastolic Blood Pressure, mmHg                                | 67 (61-72)                   | 69 (63-74)                  | 82 (80-85)                  | 83 (80-86) | 92 (89-97) | 94 (90-101) | <0.001 |
| Diabetes Mellitus, n (%)                                      | 3,791 (1.9)                  | 457 (5.8)                   | 2,429 (4.7)                 | 2,444 (5.4) | 1,859 (7.2) | 644 (10.8) | <0.001 |
| Dyslipidemia, n (%)                                           | 64,102 (32.8)                | 3,573 (45.6)                | 25,905 (49.9)               | 2,444 (54.6) | 14,583 (56.8) | 3,537 (59.3) | <0.001 |
| Cigarette Smoking, n (%)                                      | 42,824 (21.9)                | 1,738 (23.9)                | 13,180 (25.4)               | 1,038 (23.2) | 6025 (23.4) | 1,444 (24.2) | <0.001 |
| Laboratory Data                                               |                            |                            |                            |         |        |        |        |
| Glucose, mg/dL                                                | 91 (86-97)                   | 94 (88-101)                 | 95 (89-102)                 | 97 (91-105) | 97 (91-106) | 99 (92-108) | <0.001 |
| LDL-C, mg/dL                                                  | 117 (97-139)                 | 125 (104-145)               | 127 (106-148)               | 129 (108-150) | 131 (109-153) | 132 (110-154) | <0.001 |
| HDL-C, mg/dL                                                  | 65 (54-77)                   | 63 (52-77)                  | 60 (50-73)                  | 60 (50-72) | 60 (50-73) | 60 (50-72) | <0.001 |
| Triglycerides, mg/dL                                          | 72 (53-105)                  | 83 (60-120)                 | 95 (66-142)                 | 98 (69-145) | 105 (73-155) | 108 (76-162) | <0.001 |

Data are expressed as median (interquartile range) or number (percentage). *P*-values were calculated using chi-square tests for categorical variables and the analysis of variance for continuous variables. Normal blood pressure is defined as untreated systolic blood pressure <120 mm Hg and diastolic blood pressure <80 mm Hg. Elevated blood pressure is defined as untreated systolic blood pressure 120-129 mm Hg and diastolic blood pressure <80 mm Hg. Stage 1 hypertension is defined as untreated systolic blood pressure 130-139 mm Hg or diastolic blood pressure 80-89 mm Hg. Stage 2 hypertension is defined as untreated systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg. Retinal arteriolosclerosis is defined as Keith–Wagener-Barker system grade ≥ 1. ACC; American College of Cardiology, AHA; American Heart Association, LDL-C; low-density lipoprotein cholesterol, HDL-C; high-density lipoprotein cholesterol.
Fig. 2. The Frequency of Events, Corresponding Incidence Rates, and HRs for CVD Events

The incidence rate was per 10000 person-years. Unadjusted and adjusted hazard ratios (95% CI) are presented. Model 1 is unadjusted. Model 2 includes adjustment for age and sex. Model 3 includes adjustment for age, sex, obesity, high waist circumference, diabetes mellitus, dyslipidemia, and cigarette smoking. Each participant is classified into six groups: (1) normal BP or elevated BP without RA, (2) normal BP or elevated BP with RA, (3) stage 1 hypertension without RA, (4) stage 1 hypertension with RA, (5) stage 2 hypertension without RA, and (6) stage 2 hypertension with RA. (A) Myocardial infarction. (B) Angina pectoris. (C) Stroke. (D) Heart failure.

(BP Classification) RA Number No. of events Incidence Rate (95% CI) Model 1 Model 2 Model 3
Normal Blood Pressure 19534780 2702 41.6 (40.9-42.3) [Ref] [Ref] [Ref]
Elevated Blood Pressure + 7830 79 67.6 (58.4-78.3) 1.63 (1.40-1.90) 1.80 (1.68-2.04) 1.72 (1.59-1.88)
Stage 1 Hypertension - 51484 140 66.1 (62.4-70.0) 1.59 (1.45-1.73) 1.72 (1.55-1.92) 1.68 (1.52-1.87)
+ 4473 143 96.1 (81.7-112.5) 2.32 (2.06-2.63) 2.72 (2.40-3.08) 2.63 (2.32-3.00)
Stage 2 Hypertension - 25485 921 112.3 (105.3-119.3) 2.70 (2.50-2.91) 3.06 (2.84-3.31) 2.94 (2.72-3.20)
+ 5964 290 135.0 (126.4-147.6) 3.49 (3.27-3.72) 3.97 (3.72-4.23) 3.87 (3.66-4.11)
P for trend < 0.001 < 0.001 < 0.001

(C) Stroke

BP Classification RA Number No. of events Incidence Rate (95% CI) Model 1 Model 2 Model 3
Normal Blood Pressure 19534780 1421 21.8 (20.7-23.0) [Ref] [Ref] [Ref]
Elevated Blood Pressure + 7830 131 49.1 (41.5-58.5) 2.27 (1.90-2.72) 2.38 (2.04-2.82) 2.29 (1.96-2.69)
Stage 1 Hypertension - 51484 674 53.3 (50.4-56.3) 1.52 (1.38-1.67) 1.55 (1.41-1.70) 1.52 (1.38-1.67)
+ 4473 101 67.9 (55.6-82.0) 1.58 (1.34-1.86) 1.66 (1.42-1.96) 1.65 (1.41-1.95)
Stage 2 Hypertension - 25485 484 82.3 (73.3-91.3) 2.07 (1.88-2.30) 2.16 (1.96-2.40) 2.08 (1.87-2.34)
+ 5964 179 90.2 (80.4-100.9) 2.49 (2.21-2.81) 2.67 (2.40-3.00) 2.59 (2.32-2.91)
P for trend < 0.001 < 0.001 < 0.001

(D) Heart Failure

BP Classification RA Number No. of events Incidence Rate (95% CI) Model 1 Model 2 Model 3
Normal Blood Pressure 19534780 2702 41.6 (40.9-42.3) [Ref] [Ref] [Ref]
Elevated Blood Pressure + 7830 179 67.6 (58.4-78.3) 1.63 (1.40-1.90) 1.97 (1.76-2.21) 1.87 (1.66-2.12)
Stage 1 Hypertension - 51484 140 66.1 (62.4-70.0) 1.59 (1.45-1.73) 1.72 (1.55-1.92) 1.68 (1.52-1.87)
+ 4473 143 96.1 (81.7-112.5) 2.32 (2.06-2.63) 2.72 (2.40-3.08) 2.63 (2.32-3.00)
Stage 2 Hypertension - 25485 921 112.3 (105.3-119.3) 2.70 (2.50-2.91) 3.06 (2.84-3.31) 2.94 (2.72-3.20)
+ 5964 290 135.0 (126.4-147.6) 3.49 (3.27-3.72) 3.97 (3.72-4.23) 3.87 (3.66-4.11)
P for trend < 0.001 < 0.001 < 0.001
The Frequency of Events, Corresponding Incidence Rates, and HRs for CVD Events After Multiple Imputation for Missing Data

The incidence rate was per 10000 person-years. Unadjusted and adjusted hazard ratios (95% CI) are presented. Model 1 is unadjusted. Model 2 includes adjustment for age and sex. Model 3 includes adjustment for age, sex, obesity, high waist circumference, diabetes mellitus, dyslipidemia, and cigarette smoking. Each participant is classified into six groups: (1) normal BP or elevated BP without RA, (2) normal BP or elevated BP with RA, (3) stage 1 hypertension without RA, (4) stage 1 hypertension with RA, (5) stage 2 hypertension without RA, and (6) stage 2 hypertension with RA. (A) Myocardial infarction. (B) Angina pectoris. (C) Stroke. (D) Heart failure. Normal BP is defined as untreated systolic BP < 120 mm Hg and diastolic BP < 80 mm Hg. Elevated BP is defined as untreated systolic BP of 120–129 mm Hg and diastolic BP < 80 mm Hg. Stage 1 hypertension is defined as untreated systolic BP of 130–139 mm Hg or diastolic BP of 80–89 mm Hg. Stage 2 hypertension is defined as untreated systolic BP ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg. RA is defined as Keith–Wagener–Barker system grade ≥ 1. BP, blood pressure; RA, retinal arteriolosclerosis.

Fig. 3. The Frequency of Events, Corresponding Incidence Rates, and HRs for CVD Events After Multiple Imputation for Missing Data
Table 2. Subgroup Analysis

(A) Age ≥ 50 years

| BP Classification                      | Myocardial Infarction | Angina Pectoris | Stroke | Heart Failure |
|----------------------------------------|-----------------------|-----------------|--------|--------------|
| Normal BP/Elevated BP                  | (-) 109 [Reference]   | 1435 [Reference] | 774 [Reference] | 1281 [Reference] |
| (+) 12 (0.53-1.77)                     | 151 (1.04-1.24)       | 107 (1.29-1.61) | 127 (0.78-1.12) |
| Stage 1 Hypertension                   | (-) 65 (0.90-1.67)    | 678 (1.14-1.25) | 361 (0.99-1.28) | 648 (1.18-1.30) |
| (+) 14 (0.94-2.89)                     | 112 (1.04-1.53)       | 75 (1.18-1.90)  | 112 (1.09-1.61) |
| Stage 2 Hypertension                   | (-) 58 (1.31-2.51)    | 450 (1.23-1.11-1.38) | 327 (1.46-1.90) | 514 (1.37-1.70) |
| (+) 24 (1.45-3.56)                     | 170 (1.53-1.30-1.80) | 129 (1.77-2.58) | 185 (1.51-2.07) |
| P for trend                             | <0.001                | <0.001          | <0.001  | <0.001       |

(B) Age < 50 years

| BP Classification                      | Myocardial Infarction | Angina Pectoris | Stroke | Heart Failure |
|----------------------------------------|-----------------------|-----------------|--------|--------------|
| Normal BP/Elevated BP                  | (-) 132 [Reference]   | 1666 [Reference] | 647 [Reference] | 1421 [Reference] |
| (+) 3 (0.26-2.57)                      | 52 (0.95-1.66)        | 24 (0.93-2.10)  | 52 (1.15-2.20) |
| Stage 1 Hypertension                   | (-) 46 (0.77-1.54)    | 550 (1.14-1.39) | 213 (1.10-1.51) | 492 (1.23-1.53) |
| (+) 6 (0.91-1.38)                      | 23 (1.80-3.97)        | 26 (1.54-2.20)  | 31 (1.07-2.20) |
| Stage 2 Hypertension                   | (-) 46 (1.61-3.29)    | 343 (1.54-1.97) | 157 (1.76-2.55) | 407 (2.26-2.85) |
| (+) 12 (1.67-5.63)                     | 88 (2.14-3.00)        | 50 (2.69-4.86)  | 105 (2.92-4.40) |
| P for trend                             | <0.001                | <0.001          | <0.001  | <0.001       |

(C) Men

| BP Classification                      | Myocardial Infarction | Angina Pectoris | Stroke | Heart Failure |
|----------------------------------------|-----------------------|-----------------|--------|--------------|
| Normal BP/Elevated BP                  | (-) 159 [Reference]   | 1455 [Reference] | 651 [Reference] | 1287 [Reference] |
| (+) 13 (0.60-1.90)                      | 116 (0.98-1.43)       | 74 (1.12-1.82)  | 112 (1.01-1.49) |
| Stage 1 Hypertension                   | (-) 94 (0.96-1.61)    | 818 (1.14-1.35) | 384 (1.14-1.47) | 752 (1.17-1.41) |
| (+) 17 (1.11-3.06)                      | 91 (1.96-1.48)        | 74 (1.51-2.46)  | 106 (1.25-1.86) |
| Stage 2 Hypertension                   | (-) 89 (1.67-2.86)    | 521 (1.37-1.69) | 333 (1.82-2.43) | 605 (1.79-2.19) |
| (+) 34 (1.94-4.17)                     | 183 (1.65-2.26)       | 124 (2.23-3.30) | 216 (2.17-2.91) |
| P for trend                             | <0.001                | <0.001          | <0.001  | <0.001       |

(D) Women

| BP Classification                      | Myocardial Infarction | Angina Pectoris | Stroke | Heart Failure |
|----------------------------------------|-----------------------|-----------------|--------|--------------|
| Normal BP/Elevated BP                  | (-) 82 [Reference]    | 1646 [Reference] | 770 [Reference] | 1415 [Reference] |
| (+) 2 (0.14-2.35)                      | 87 (0.84-1.30)        | 57 (0.96-1.65)  | 67 (0.76-1.24) |
| Stage 1 Hypertension                   | (-) 17 (0.64-1.85)    | 410 (1.04-1.30) | 190 (1.03-1.29) | 388 (1.15-1.45) |
| (+) 3 (0.70-7.25)                      | 44 (1.06-1.76)        | 27 (1.00-2.17)  | 37 (0.93-1.80) |
| Stage 2 Hypertension                   | (-) 15 (1.01-3.22)    | 272 (1.17-1.53) | 151 (1.24-1.79) | 316 (1.60-2.07) |
| (+) 2 (0.25-4.33)                      | 75 (1.23-1.97)        | 55 (1.68-2.94)  | 74 (1.43-2.31) |
| P for trend                             | 0.083                 | <0.001          | <0.001  | <0.001       |

Subgroup analyses are performed as follows: (A) Aged ≥ 50 years; (B) Age < 50 years; (C) Men; (D) Women. Results of analyses are shown in tables (A, B, C, and D). HRs (95% CI) are adjusted for age, sex, obesity, high waist circumference, diabetes mellitus, dyslipidemia, and cigarette smoking in subgroups stratified by age (A, B), or for age, obesity, high waist circumference, diabetes mellitus, dyslipidemia, and cigarette smoking in subgroups stratified by sex (C, D). BP classification and the definition of RA are the same as in table 1. BP; blood pressure, RA; retinal arteriolosclerosis, HR; hazard ratio, CI; confidence interval.
Similarly, the analysis of the US National Health and Nutrition Examination Survey and China Health and Retirement Longitudinal Study reported that the prevalence of hypertension would increase by 26.8% in the USA and by 45.1% in China and that more than half of the population aged 45–75 years in both countries would be diagnosed with hypertension according to this guideline. Due to the great clinical and epidemiological impact of this guideline, the accurate risk stratification of population classified using this guideline is essential for determining the management strategy with this guideline. Particularly, identifying the subpopulation at a higher risk of future CVD among the population categorized in stage 1 hypertension is important because the necessity of proactive BP-lowering efforts using pharmacological treatment would depend on the subsequent CVD risk of each individual.

Our results including population without a prevalent history of CVD indicated that subjects with RA defined as Keith–Wagener–Barker system grade ≥ 1 were associated with a greater risk of MI, AP, stroke, and HF than those without RA among participants with stage 1 or stage 2 hypertension. Furthermore, subjects with RA were associated with a higher incidence of stroke than those without RA even among participants categorized in the normal/elevated BP group. These results may suggest that detecting subclinical atherosclerosis would be helpful for identifying population at a high risk of future CVD.

Although our study is the first to suggest the potential benefit of the assessment of RA for CVD risk stratification of subjects classified using the 2017 ACC/AHA BP guideline, preceding studies focusing on coronary artery calcium yielded similar results. The analysis of Multi-Ethnic Study of Atherosclerosis (MESA), Coronary Artery Risk Development in Young Adults study, and Jackson Heart Study including 6,461 subjects revealed that coronary artery calcium score of >0 was associated with a higher incidence of CVD including MI and revascularization or resuscitated cardiac arrest due to cardiac causes in subjects categorized in elevated BP/stage 1 hypertension or stage 2 hypertension. Similarly, McEvoy et al. reported that a higher coronary artery calcium score was associated with a higher CVD risk among participants with baseline low CVD risk and SBP of either 120–139 mmHg or 140–159 mmHg. Uddin et al. also reported that an increase in coronary artery calcium score was associated with increased coronary heart disease and CVD mortality among hypertensive subjects.

A biomarker-based strategy is another option for facilitating BP management. The analysis of Atherosclerosis Risk in Communities Study, Dallas Heart Study, and MESA study including 12,987 subjects revealed that elevated biomarker (high-sensitivity cardiac troponin or N-terminal pro-B-type natriuretic peptide) was associated with a higher incidence of cardiovascular events defined as atherosclerotic CVD or HF in subjects with elevated BP or hypertension. Similarly, Pokharel et al. reported that higher troponin T was associated with increasing cardiovascular events, including HF hospitalization, coronary heart disease, and stroke, across most SBP categories.

Taking our results and these previous studies into consideration, detecting subclinical atherosclerosis or measuring biomarker could be clinically useful strategies for identifying population at a high risk of future CVD. However, given that RA can be evaluated in a minimally invasive and inexpensive manner, the assessment of RA could be the most useful strategy for the risk stratification for subsequent CVD events in the general population. Further investigations are required to determine the optimal approach to facilitate the management strategy for people diagnosed with hypertension according to the 2017 ACC/AHA BP guideline.

The strengths of this study include the large nationwide longitudinal population-based database including the general population without a prior history of CVD, the fact that participants were not taking any BP-lowering medications at baseline, and the high ascertainment rate of the study participants. As previously described, since the JMDC Claims Database contains medical claims records using ICD-10 codes of employee health insurance, it is theoretically possible to track all clinical events, such as the onset of CVD, as long as he or she has the same insurance, even if he or she visits multiple healthcare providers or institutions.

This study has several limitations. Although we categorized study population using BP measurements at a health check-up, BP classification based on a single-visit assessment may not represent the BP phenotype of each individual. The Japanese Ministry of Health, Labour and Welfare recommends healthcare professionals to measure BP and to conduct nonmydriatic retinal photography using the standardized protocol. However, in a real-world health check-up environment on a nationwide scale, adherence to the recommended protocols might be limited. Only data from the retinoscopy findings of one eye (right or left eye) were available. The risk of CVD could be different between Keith–Wagener–Barker system grade 1 and Keith–Wagener–Barker system grade 2 or higher. However, due to the limited
sample size, we could not analyze these subjects separately. Because the occurrence of CVD events was identified based on diagnostic codes registered in the JMDC Claims Database, uncertainty could remain regarding the accuracy of the diagnoses. Selection bias (e.g., healthy worker bias) might be present because the JMDC Claims Database obtained data mainly from an employed population of the working age. Therefore, further investigations are required to generalize our results. Although we conducted multivariable analyses, there could be unmeasured confounders or residual bias. For example, data on socioeconomic status could not be analyzed in this study.

### Conclusion

Our analysis of a nationwide epidemiological database including adults not taking any BP-lowering medications and with no prevalent history of CVD revealed that the risk of CVD events increased depending on the BP category according to the 2017 ACC/AHA BP guideline, and this association was pronounced in participants with RA defined as Keith–Wagener–Barker system grade ≥ 1. The assessment of RA would be helpful for the CVD risk stratification of people classified based on the 2017 ACC/AHA BP guideline.

### Source of Funding

This work was supported by grants from the Ministry of Health, Labour and Welfare, Japan (19AA2007 and H30-Policy-Designated-004) and the Ministry of Education, Culture, Sports, Science and Technology, Japan (17H04141). This study was funded by a grant from the Pfizer Health Research Foundation (in 2019).

### Disclosures

Research funding and scholarship funds (Hidehiro Kaneko and Katsuhito Fujiu) from Medtronic Japan CO., LTD, Boston Scientific Japan CO., LTD, Biotronik Japan, Simplex QUANTUM CO., LTD, and Fukuda Denshi, Central Tokyo CO., LTD.

### References

1) Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, D’joussé L, Elkind MS, Ferguson JF, Fornage F, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UK, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes L, Tirschwell DL, VanWagner LB, Tsao CW. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation, 2020; 141: e139-e596

2) Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 2002; 360: 1903-1913

3) Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA, 1996; 275: 1557-1562

4) Tajeu GS, Booth JN 3rd, Colantonio LD, Gottesman RF, Howard G, Lackland DT, O’Brien EC, Oparil S, Ravenell J, Safford MM, Seals SR, Shimbo D, Shea S, Spruill TM, Tanner RM, Muntpertner Incident Cardiovascular Disease Among Adults With Blood Pressure 140/90 mm Hg. Circulation, 2017; 136: 798-812

5) Wright JT Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboisson DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr., Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 2015; 373: 2103-2116

6) Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EF, Muntpertner P, Ovbiagele B, Smith SC Jr., Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr., Williamson JD, Wright JT Jr.. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2018; 138: e484-e594

7) Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Sr., Gibbons R, Greenland P, Lackland DT, Levy D, O’Donnell CJ, Robinson JG, Schwartz J, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 2014; 63: 2935-2959

8) Rana JS, Tabada GH, Solomon MD, Lo JC, Jaffe MG, Sung SH, Ballantyne CM, Go AS. Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Population. J Am Coll Cardiol, 2016; 67: 2118-2130

9) O’Leary DH, Polak JF, Krommal RA, Manolio TA, Burke GL and Wolfson SK, Jr.. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med, 1999; 340: 14-22
| Page | Author(s) | Reference |
|------|-----------|------------|
| 10   | Lorenz MW, Markus HS, Bots ML, Rosvall M and Sitzer M. | Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation, 2007; 115: 459-467 |
| 11   | Effoe VS, Rodriguez CJ, Wagenknecht LE, Evans GW, Chang PP, Mirabelli MC, Bertoni AG. | Carotid intima-media thickness is associated with incident heart failure among middle-aged whites and blacks: the Atherosclerosis Risk in Communities study. J Am Heart Assoc, 2014; 3: e007977 |
| 12   | Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szkl M, Bluemke DA, O'Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA. | Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med, 2008; 358: 1336-1345 |
| 13   | Kim GH, Youn HJ, Kang S, Choi YS, Moon JJ. | Relation between grade II hypertensive retinopathy and coronary artery disease in treated essential hypertensives. Clin Exp Hypertens, 2010; 32: 469-473 |
| 14   | Sairenchi T, Iso H, Yamagishi K, Irie F, Okubo Y, Gunji J, Muto T and Ota H. | Mild retinopathy is a risk factor for cardiovascular mortality in Japanese with and without hypertension: the Ibaraki Prefectural Health Study. Circulation, 2011; 124: 2502-2511 |
| 15   | Zhang W, Li J, Zhao L, Zhang J, He H, Meng Y, Peng Y, Shang K, Zhang Y, Gu X, Chen X, Zhang Y, Yang Y, Sun P, Qin X, Wang B, Xu X, Hou F, Tang G, Liao R, Lin T, Jiang C, Huo Y, Yang L. | Positive relationship of hypertensive retinopathy with carotid intima-media thickness in hypertensive patients. J Hypertens, 2020; 38: 2028-2035 |
| 16   | Ohbe H, Goto T, Miyamoto Y and Yasunaga H. | Risk of Cardiovascular Events After Spouse's ICU Admission. Circulation, 2020; 142: 1691-1693 |
| 17   | Kaneko H, Itoh H, Yotsumoto H, Kiriyama H, Kamon T, Fujiu K, Morita K, Michihata N, Jo T, Morita H, Yasunaga H, Komuro I. | Association of body weight gain with subsequent cardiovascular event in non-obese general population without overt cardiovascular disease. Atherosclerosis, 2020; 308: 39-44 |
| 18   | Goto A, Goto M, Terauchi Y, Yamaguchi N, Noda M. | Association Between Severe Hypoglycemia and Cardiovascular Disease Risk in Japanese Patients With Type 2 Diabetes. J Am Heart Assoc, 2016; 5: e002875 |
| 19   | Wake M, Onishi Y, Guelfucci F, Oh A, Hiroi S, Shimasaki Y, Teramoto T. | Treatment patterns in hyperlipidemia patients based on administrative claim databases in Japan. Atherosclerosis, 2018; 272: 145-152 |
| 20   | Kawasakri R, Konta T, Nishida K. | Lipid-lowering medication is associated with decreased risk of diabetic retinopathy and the need for treatment in patients with type 2 diabetes: A real-world observational analysis of a health claims database. Diabetes Obes Metab, 2018; 20: 2351-2360 |
| 21   | Kaneko H, Itoh H, Kiriyama H, Kamon T, Fujiu K, Morita K, Michihata N, Jo T, Takeda N, Morita H, Yasunaga H, Komuro I. Lipid Profile and Subsequent Cardiovascular Disease among Young Adults Aged <50 Years. Am J Cardiol, 2021; 142: 59-65 |
| 22   | Kaneko H, Itoh H, Yotsumoto H, Kiriyama H, Kamon T, Fujiu K, Morita K, Kashiwabara K, Michihata N, Jo T, Morita H, Yasunaga H, Komuro I. | Cardiovascular Health Metrics of 87,160 Couples: Analysis of a Nationwide Epidemiological Database. J Atheroscler Thromb, 2021; 28: 535-543 |
| 23   | Yasunaga H. | Real World Data in Japan: Chapter I NDB. Annals of Clinical Epidemiology 2019; 1: 28-30 |
| 24   | Keith NM, Wagener HP, Barker NW. | Some different types of essential hypertension: their course and prognosis. Am J Med Sci, 1974; 268: 336-345 |
| 25   | Matsuoka S, Kaneko H, Yano Y, Itoh H, Fukui A, Morita K, Kiriyama H, Komuro I, Sasaki Y, Aoki T, Nakamura S, Yokoo T, Nishiyama A, Node K, Yasunaga H, Komuro I. | Association Between Blood Pressure Classification Using the 2017 ACC/AHA Blood Pressure Guideline and Retinal Atherosclerosis. Am J Hypertens, 2021; 34: 1049-1056 |
| 26   | Itoh H, Kaneko H, Kiriyama H, Yoshiida Y, Nakanishi K, Mizuno Y, Daimon M, Morita H, Yatomi Y, Yamamichi N, Komuro I. | Effect of Metabolically Healthy Obesity on the Development of Carotid Plaque in the General Population: A Community-Based Cohort Study. J Atheroscler Thromb, 2020; 27: 155-163 |
| 27   | Matsuzawa Y. | Metabolic syndrome--definition and diagnostic criteria in Japan. J Atheroscler Thromb, 2005; 12: 301 |
| 28   | Yagi M, Yasunaga H, Matsu H, Morita K, Fushimi K, Fujimoto M, Koyama T, Fujitani J. | Impact of Rehabilitation on Outcomes in Patients With Ischemic Stroke: A Nationwide Retrospective Cohort Study in Japan. Stroke, 2017; 48: 740-746 |
| 29   | Aloisio KM, Swanson SA, Micali N, Field A, Horton NJ. | Analysis of partially observed clustered data using generalized estimating equations and multiple imputation. Stata J, 2014; 14: 863-883 |
| 30   | Rubin DB, Schenker N. | Multiple imputation in health-care databases: an overview and some applications. Stat Med, 1991; 10: 585-598 |
| 31   | Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT, Jr., Whelton PK. | Potential US Population Impact of the 2017 ACC/AHA Blood Pressure Guideline. Circulation, 2018; 137: 109-118 |
| 32   | Khera R, Lu Y, Lu J, Saxena A, Nasir K, Jiang L, Krumbholz HM. | Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study. BMJ, 2018; 362: k2357 |
| 33   | Parcha V, Malla G, Kalra R, Li P, Pandey A, Nasir K, Arora G, Arora P. | Coronary Artery Calcium Score for Personalization of Antihypertensive Therapy: A Pooled Cohort Analysis. Hypertension, 2021; 77: 1106-1118 |
| 34   | McEvoy JW, Martin SS, Battah ZA, Miedema MD, Sandfort V, Veleboj J, Budoff MJ, Goff DC, Jr., Psaty BM, Post WS, Nasir K, Blumenthal RS, Blaha MJ. | Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and Intensification of Antihypertensive Therapy. Circulation, 2017; 135: 153-165 |
| 35   | Uddin SMI, Mirbolouk M, Kianoush S, Orimoloye OA, | Retinal Arteriosclerosis, BP, CVD Risk |
36) Pandey A, Patel KV, Vongpatanasin W, Ayers C, Berry JD, Mentz RJ, Blaha MJ, McEvoy JW, Muntner P, Vaduganathan M, Correa A, Butler J, Shimbo D, Nambi V, Filippi C, Seliger SL, Ballantyne CM, Selvin E, Lemos JA, Joshi PH. Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. Circulation, 2019; 140: 2076-2088

37) Pokharel Y, Sun W, de Lemos JA, Taffet GE, Virani SS, Ndumele CE, Mosley TH, Hoogeveen RC, Coresh J, Wright JD, Heiss G, Boerwinkle EÁ, Bozkurt B, Solomon SD, Ballantyne CM, Nambi V. High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities study. Hypertension, 2015; 65: 983-989

38) Kaneko H, Yano Y, Itoh H, Morita K, Kiriyama H, Kamon T, Fujita N, Michihata N, Jo T, Takeda N, Morita H, Node K, Carey RM, Lima JA, Oparil S, Yasunaga H, Komuro I. Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation. Circulation, 2021; 143: 2244-2253